FCA Corp’s Teva Pharmaceuticals TEVA Stock Holding History

FCA Corp’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-16,000	Closed	-$389K	–	165
2018 Q2	$389K	Hold	16,000	–	–	0.16%	100
2018 Q1	$273K	Hold	16,000	–	–	0.11%	120
2017 Q4	$303K	Hold	16,000	–	–	0.12%	121
2017 Q3	$282K	Buy	16,000 +8,000	+100%	+$180K	0.12%	118
2017 Q2	$266K	Buy	+8,000	New	+$248K	0.12%	119
2014 Q4	–	Sell	-6,000	Closed	-$323K	–	136
2014 Q3	$323K	Hold	6,000	–	–	0.18%	92
2014 Q2	$315K	Hold	6,000	–	–	0.17%	96
2014 Q1	$318K	Hold	6,000	–	–	0.19%	86
2013 Q4	$241K	Hold	6,000	–	–	0.14%	105
2013 Q3	$227K	Hold	6,000	–	–	0.13%	115
2013 Q2	$235K	Buy	+6,000	New	+$234K	0.15%	102

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

FCA Corp's TEVA Position: Q3 2018 in Review

FCA Corp sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 16,000 shares — an estimated $389K sold.

FCA Corp first reported a position in TEVA in Q2 2013 and held it in 11 quarters. The position peaked at $389K in Q2 2018. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

FCA Corp reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
FCA Corp sold 16,000 Teva Pharmaceuticals shares in Q3 2018, an estimated $389K.
FCA Corp first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 11 quarters.
FCA Corp's Teva Pharmaceuticals position peaked at $389K in Q2 2018.
556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on FCA Corp's 13F filing for Q3 2018, filed 22 Oct 2018.